EL7.AI
StocksMedium•23 July 2026•
1 min read

Quest Diagnostics Beats Q2 Estimates and Provides Positive Full-Year Revenue Guidance

Key Facts

1Quest Diagnostics reported Q2 revenue of $3.04 billion, surpassing FactSet estimates of $2.97 billion.
2The company posted Q2 adjusted EPS of $3.12 per share, exceeding the FactSet estimate of $2.82.
3The company expects full-year 2026 revenue to be between $11.95 billion and $12.05 billion.

In a move reflecting the robust performance of the medical diagnostic services sector, Quest Diagnostics reported second-quarter financial results that significantly exceeded market expectations. The company posted revenue of $3.04 billion, surpassing analyst estimates of $2.97 billion, while adjusted earnings per share reached $3.12 compared to the anticipated $2.82. This outperformance is attributed to stronger-than-expected demand in diagnostic testing and information services.

Following this strong performance, the company updated its outlook for 2026, forecasting full-year revenue to range between $11.95 billion and $12.05 billion. Per market data, this guidance suggests continued growth momentum in healthcare services, reinforcing the company's position within the large-cap healthcare sector as it maintains positive operational trajectory.

Regarding market performance, DGX shares closed at $209.83 (as of July 22, 2026), having reached a session high of $212.3. With no immediate sector-specific catalysts in the upcoming economic calendar, investors will likely focus on the stock's ability to maintain its current levels following the positive earnings surprise.